Literature DB >> 29232339

The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges.

Nitya Raj1, Diane Reidy-Lagunes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29232339      PMCID： PMC5729934          DOI： 10.1097/MPA.0000000000000949

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  16 in total

1.  Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?

Authors:  Diane L Reidy-Lagunes; Marc J Gollub; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Authors:  Martyn E Caplin; Marianne Pavel; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.

Authors:  Jörg Kowalski; Marcus Henze; Jochen Schuhmacher; Helmut R Mäcke; Michael Hofmann; Uwe Haberkorn
Journal:  Mol Imaging Biol       Date:  2003 Jan-Feb       Impact factor: 3.488

5.  Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.

Authors:  Stefano Fanti; Valentina Ambrosini; Paola Tomassetti; Paolo Castellucci; Giancarlo Montini; Vincenzo Allegri; Gaia Grassetto; Domenico Rubello; Cristina Nanni; Roberto Franchi
Journal:  Biomed Pharmacother       Date:  2008-03-03       Impact factor: 6.529

6.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

8.  Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

Authors:  Narek Shaverdian; Scott N Pinchot; Barbara Zarebczan; Holly C Gillis; Adam Schiro; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2012-09-01       Impact factor: 5.344

9.  The status of neuroendocrine tumor imaging: from darkness to light?

Authors:  Lisa Bodei; Anders Sundin; Mark Kidd; Vikas Prasad; Irvin M Modlin
Journal:  Neuroendocrinology       Date:  2014-09-10       Impact factor: 4.914

Review 10.  Imaging of neuroendocrine tumors.

Authors:  Eric P Tamm; E Edmund Kim; Chaan S Ng
Journal:  Hematol Oncol Clin North Am       Date:  2007-06       Impact factor: 3.722
View more
  3 in total

Review 1.  Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.

Authors:  George Crișan; Nastasia Sanda Moldovean-Cioroianu; Diana-Gabriela Timaru; Gabriel Andrieș; Călin Căinap; Vasile Chiș
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.

Authors:  Shilpa Thakur; Brianna Daley; Corina Millo; Craig Cochran; Orit Jacobson; Huiyan Lu; Zhantong Wang; Dale Kiesewetter; Xiaoyuan Chen; Vasyl Vasko; Joanna Klubo-Gwiezdzinska
Journal:  Clin Cancer Res       Date:  2020-12-22       Impact factor: 13.801

Review 3.  Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update.

Authors:  Efstathios Theodoros Pavlidis; Theodoros Efstathios Pavlidis
Journal:  World J Clin Cases       Date:  2022-09-26       Impact factor: 1.534
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.